Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. Additional information about Twist Boston, also known as Abveris, is available at About Twist Bioscience Corporation Twist Boston is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders.
The company applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Twist Boston provides premium in vivo antibody discovery services to the biopharma industry. Twist has the option to expand the size of the site to accommodate future growth. The new Twist Boston location boasts state-of-the-art antibody discovery workflow tools, including a total of four Berkeley Lights Beacon ® Optofluidic Platforms, for increased screening capacity for discovery projects necessitating ultra-rapid high-content function forward screening. Antibodies discovered using the DiversimAb platform can be humanized using the Twist antibody optimization (TAO) platform to develop superior biologics for rapid clinical advancement. Twist Boston empowers the development of the next generation of biologics, cell therapies, vaccines, and diagnostics by using its DiversimAb™ family of hyperimmune mouse models to complete discovery and characterization services for global biopharma leaders.
Twist Boston, formerly known as Abveris, was acquired by Twist Bioscience in November 2021 to add in vivo antibody discovery expertise to Twist Biopharma’s antibody discovery and optimization capabilities using robust, precisely written synthetic libraries.
“Twist is one of the first biotech companies to open a site in Quincy, and we were pleased to find an ideal space that fits our aggressive growth plans to serve our biopharma partners in accelerating antibody discovery for a wide range of therapeutic targets.” Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “This is a year of growth for Twist, as we work to bring the Factory of the Future online in Oregon while expanding our in vivo antibody discovery capacity through our new Twist Boston location,” said Emily M.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the opening of its new Twist Boston location in Quincy, Massachusetts. SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Jul. New facility increases in vivo antibody discovery capacity
0 kommentar(er)
